RxDoctor Payments Data

Wei Liu

Vascular Neurology · Louisville, KYNPI 1720277684

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (49.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.8%. Reporting peaked in 2022 at $2,872 and has fallen 95.4% since, to $132 in 2025.

$7,390in general payments, 2019–2025

Across 74 payments — averaging $99.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Shionogi Inc$1K
  • Biogen$1K
  • Janssen Research & Development, LLC$968
  • ZOLL Medical Corporation$747
  • BD$374
  • plus $1K from 10 others
$311,825in research payments, 2019–2025

Across 60 payments — averaging $5197.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$129K
  • Biogen$114K
  • E.r. Squibb & Sons, L.L.C.$52K
  • Sunovion Pharmaceuticals Inc.$16K

What the payments were for

  • Consulting fees$1,24517%
  • Travel & lodging$3,62049%
  • Food & beverage$2,52534%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular neurology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$36,257
Medicare patients
121
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$44,275
XareltoRivaroxaban32$26,072
BrilintaTicagrelor12$9,472
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine23$957
Memantine Hcl39$856
ClopidogrelClopidogrel Bisulfate125$795
Atorvastatin Calcium73$694
Rosuvastatin Calcium48$586
Gabapentin55$451
Pantoprazole Sodium73$446
Amlodipine Besylate57$239
Lisinopril42$106
Topiramate16$91
Baclofen16$77
Carvedilol11$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$16$26,07232 claims
AstraZenecaBrilinta$47$9,47212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.

Other vascular neurology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →